Mitochondrial-Derived Peptides: The Anti-Aging Class

Mitochondrial Peptides

8 known MDPs

Eight peptides encoded in mitochondrial DNA have been identified so far: humanin, MOTS-c, and six small humanin-like peptides (SHLPs 1-6).

Merry et al., American Journal of Physiology, 2020

Merry et al., American Journal of Physiology, 2020

View as image

Your mitochondria make more than energy. Small open reading frames within the 16,569-base-pair mitochondrial genome encode at least eight peptides that function as signaling molecules throughout the body. These mitochondrial-derived peptides (MDPs) include humanin (discovered in 2001), MOTS-c (identified in 2015), and six small humanin-like peptides (SHLPs 1-6).^[1] Their levels decline with age, and their functions intersect with nearly every major aging pathway: AMPK activation, insulin sensitivity, inflammation, apoptosis, and oxidative stress. For a deep look at humanin's cytoprotective mechanisms, see our pillar article. This article maps the full MDP family, what each member does, and where the evidence stands.

What makes mitochondrial-derived peptides different

Most peptide drugs are synthetic analogs of nuclear-encoded hormones: insulin, GLP-1, GnRH, alpha-MSH. MDPs are fundamentally different because they originate from the mitochondrial genome, a 16,569-base-pair circular DNA molecule inherited exclusively from the maternal lineage.

For decades, the mitochondrial genome was thought to encode only 13 proteins (all involved in oxidative phosphorylation), 22 transfer RNAs, and 2 ribosomal RNAs. The discovery that small open reading frames (sORFs) within these known genes could produce bioactive peptides reframed mitochondria as endocrine organelles, not just power generators.

Merry et al.'s 2020 review in the American Journal of Physiology documented the emerging evidence that MDPs act as retrograde signals from mitochondria to the nucleus, communicating mitochondrial stress status to the rest of the cell and, when secreted, to distant tissues.^[1] This positions MDPs as a communication system that declines with age as mitochondrial function deteriorates.

Humanin: the first and most studied

Humanin was discovered in 2001 by Tajima et al., who identified a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene of mitochondrial DNA.^[2] It was found while screening for genes that could protect neurons from amyloid-beta toxicity in Alzheimer's disease. The peptide blocked apoptosis induced by three different familial AD-associated mutant genes.

Since then, humanin's functions have expanded well beyond neuroprotection:

Cytoprotection. Humanin protects cells against apoptosis through multiple pathways, including interaction with Bax (a pro-apoptotic protein) and activation of the STAT3 signaling pathway. Hazafa et al.'s 2021 review cataloged humanin's protective effects in models of Alzheimer's disease, cardiovascular disease, diabetes, and age-related macular degeneration.^[3]

Cardiovascular protection. Qin et al. (2018) demonstrated that chronic treatment with the humanin analog HNG prevented age-related myocardial fibrosis and diastolic dysfunction in mice. The treatment reduced collagen deposition, decreased oxidative stress markers, and improved cardiac function in aged animals.^[4]

Lifespan regulation. Yen et al. (2020) published evidence that humanin regulates lifespan and healthspan across species. GH receptor knockout mice (which live approximately 40% longer than normal) have elevated humanin levels. Centenarians have higher circulating humanin than age-matched controls.^[5]

Age-related decline. Humanin levels in cerebrospinal fluid decline with age, and lower levels correlate with cognitive impairment. This decline parallels the broader deterioration of mitochondrial function that characterizes aging. For more on why mitochondrial decline drives aging, see the dedicated article.

MOTS-c: the exercise mimetic

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) was identified in 2015 by Lee et al. at the University of Southern California. It is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA.^[6]

The discovery paper in Cell Metabolism demonstrated that MOTS-c targets the folate-methionine cycle, activates AMPK, and promotes metabolic homeostasis. Mice treated with MOTS-c were protected from obesity and insulin resistance on a high-fat diet.^[6] Lee's 2016 follow-up detailed MOTS-c's dual role in regulating both muscle and fat metabolism.^[7]

MOTS-c and exercise

One of the most compelling findings about MOTS-c is its relationship with physical activity. Reynolds et al. (2021) published a landmark study in Nature Communications showing that MOTS-c is an exercise-induced regulator of age-dependent physical decline.^[8] Key findings:

• Exercise increases circulating MOTS-c levels in both young and old mice
• MOTS-c administration improved physical capacity in old mice, mimicking some effects of exercise
• MOTS-c prevented muscle wasting (sarcopenia) in aging animals
• The peptide's effects were mediated through AMPK-dependent pathways in skeletal muscle

This positions MOTS-c as one of the first endogenous "exercise mimetic" peptides, a molecule whose levels rise with exercise and whose exogenous administration partially reproduces exercise benefits. For the detailed AMPK mechanism, see the article on how MOTS-c activates AMPK.

Dieli-Conwright et al. (2021) extended this to human cancer survivors, showing that both aerobic and resistance exercise altered circulating MOTS-c levels in Hispanic and non-Hispanic white breast cancer survivors.^[9] The exercise-MOTS-c response varied by ethnicity and exercise type, suggesting that genetic variation in the mitochondrial genome influences MDP responses.

MOTS-c nuclear translocation

Kim et al. (2018) published a mechanistic breakthrough showing that MOTS-c translocates from the cytoplasm to the nucleus under metabolic stress, where it directly regulates gene expression through antioxidant response elements (AREs).^[10] This was the first demonstration that a mitochondrial-encoded peptide could act as a nuclear transcription regulator, bridging mitochondrial metabolism and nuclear gene expression. The finding fundamentally changed how researchers view mitochondrial-nuclear communication.

MOTS-c in clinical trials

MOTS-c is the first MDP to enter formal clinical testing. Two clinical trials are registered:

• NCT04027712: Evaluating MOTS-c for coronary artery disease in patients with type 2 diabetes
• NCT03998514: Testing a MOTS-c analog (CB4211) for nonalcoholic fatty liver disease and obesity

Zheng et al.'s 2023 review noted that while preclinical data is promising, significant challenges remain for clinical translation, including peptide stability, delivery optimization, and determining whether exogenous MOTS-c can replicate the endogenous peptide's tissue-specific effects.^[11]

SHLPs: the least-known family members

Six small humanin-like peptides (SHLPs 1-6) were identified within the mitochondrial 16S rRNA gene, the same gene that encodes humanin. Each SHLP is 20-38 amino acids long. Their functions are less characterized than humanin or MOTS-c, but early research suggests distinct biological roles:

• SHLP2: Protects cells against amyloid-beta toxicity and age-related macular degeneration; promotes cell survival through anti-apoptotic signaling
• SHLP3: Promotes mitochondrial biogenesis, reduces reactive oxygen species, and decreases mitochondrial DNA oxidation
• SHLP6: Promotes apoptosis (the opposite of most MDPs), suggesting a role in quality control rather than cell preservation

For a complete analysis of SHLPs and their emerging biology, see the dedicated article. The functional diversity within the SHLP family suggests that the mitochondrial genome encodes a nuanced signaling toolkit, not just a set of generic protective factors.

How MDPs connect to aging pathways

MDPs intersect with the major molecular pathways implicated in aging:

AMPK. MOTS-c directly activates AMP-activated protein kinase, the cellular energy sensor that promotes catabolic metabolism, autophagy, and mitochondrial biogenesis. AMPK activation is one of the most consistently replicated longevity interventions across species. The connection between MOTS-c and AMPK represents a direct link between mitochondrial signaling and a core aging mechanism.

Insulin/IGF-1 signaling. Humanin improves insulin sensitivity in animal models. MOTS-c does the same through a different mechanism (AMPK-mediated glucose uptake rather than insulin receptor modulation). The long-lived GH receptor knockout mice that have elevated humanin also have reduced IGF-1 signaling, placing humanin at the intersection of two major longevity pathways.^[5]

Inflammation. Humanin suppresses inflammatory signaling, including NF-kB pathway activation. This anti-inflammatory effect has been demonstrated in models of atherosclerosis, neurodegeneration, and cardiac aging.^[4]

Apoptosis. Humanin's original function was blocking neuronal apoptosis. This extends to protection against oxidative stress-induced cell death in cardiac, retinal, and pancreatic cells.^[3]

Telomere biology. While MDPs do not directly affect telomerase, the mitochondrial decline that reduces MDP production overlaps with telomere shortening as a hallmark of aging. For comparison, epithalon's proposed telomerase-activating mechanism represents a different anti-aging peptide approach entirely.

The cancer question

Zuccato et al.'s 2019 review raised an important caveat: humanin's anti-apoptotic activity, which protects healthy cells from dying, could theoretically protect cancer cells as well.^[12] Some cancer types express elevated humanin levels, potentially using the peptide to resist chemotherapy-induced cell death. This dual-edged nature is common in cytoprotective pathways (the same anti-apoptotic signaling that prevents neurodegeneration can also prevent tumors from responding to treatment).

This does not mean MDPs cause cancer. It means that any therapeutic application of MDPs, particularly humanin, will need to account for context: protecting neurons from amyloid-beta toxicity is desirable, but protecting tumor cells from treatment is not. The specificity challenge is one reason MDP therapeutics remain in early development.

Genetic variation changes MDP function

Because MDPs are encoded in mitochondrial DNA, genetic variation in mtDNA directly affects their amino acid sequences and biological activity. This is a dimension of pharmacogenomics that nuclear-encoded peptide drugs do not face.

Zempo et al. (2021) identified a common mtDNA polymorphism (m.1382A>C) in the MOTS-c gene that changes a lysine to glutamine at position 14. This variant MOTS-c has reduced ability to regulate insulin signaling and is associated with increased type 2 diabetes risk in Japanese populations. The polymorphism occurs at different frequencies across ethnic groups, suggesting that MDP biology varies by ancestry.

This has implications for both research interpretation and future therapeutics. A MOTS-c therapeutic designed around the reference sequence may not work the same way in individuals carrying the K14Q variant. Similarly, the exercise-MOTS-c response documented by Dieli-Conwright et al. varied between Hispanic and non-Hispanic white breast cancer survivors, a finding that may partly reflect mtDNA variation between these populations.^[9]

Humanin's sequence also varies across mitochondrial haplogroups. Whether these variants have meaningful functional differences is an active area of investigation. The broader point is that MDPs sit at the intersection of mitochondrial genetics and peptide therapeutics, a space that most drug development pipelines have not yet learned to navigate.

MDPs vs. mitochondrial-targeting peptides

MDPs should not be confused with synthetic mitochondrial-targeting peptides like SS-31 (elamipretide). SS-31 is a synthetic tetrapeptide designed to penetrate mitochondrial membranes and bind cardiolipin on the inner mitochondrial membrane, stabilizing the electron transport chain. It is not encoded in mtDNA. For details on how SS-31 targets mitochondrial dysfunction, see the dedicated article.

The distinction matters: MDPs are endogenous signaling molecules whose levels decline with age. SS-31 is an exogenous drug designed to fix mitochondrial mechanics. They address different aspects of mitochondrial aging and are not interchangeable, though both fall under the broad umbrella of "mitochondrial peptide therapeutics."

Where the evidence stands

The MDP field is in a transitional phase between preclinical discovery and clinical validation:

Strong preclinical evidence exists for MOTS-c in metabolic disease (obesity, insulin resistance, NAFLD) and for humanin in neuroprotection and cardiac aging. Multiple animal studies show consistent protective effects.

Human observational data is accumulating showing that endogenous MDP levels decline with age, correlate with metabolic health, and respond to exercise. But these are association studies, not interventional trials.

Clinical trials are early-stage. The two registered MOTS-c trials represent the first controlled tests of whether exogenous MDP administration produces clinical benefit in humans. Results have not yet been published.

Delivery remains a challenge. MDPs are small peptides with short half-lives. Developing formulations that maintain bioactivity and reach target tissues at therapeutic concentrations is an active area of research.

The gap between what MDPs can do in a petri dish and what they can do in a person has not been bridged. The biology is compelling; the clinical evidence is not yet there.

The Bottom Line

Mitochondrial-derived peptides represent a new class of signaling molecules encoded in mitochondrial DNA. Humanin protects against apoptosis and neurodegeneration. MOTS-c functions as an exercise mimetic that activates AMPK and improves metabolic health. Six SHLPs add further complexity. All decline with age. MOTS-c has entered clinical trials for metabolic disease, making it the first MDP to be tested as a therapeutic in humans. The field holds promise but remains largely preclinical, with significant delivery and specificity challenges still unresolved.

Frequently Asked Questions

What are mitochondrial-derived peptides?

Mitochondrial-derived peptides (MDPs) are small bioactive peptides encoded within the mitochondrial genome. Eight have been identified: humanin (24 amino acids), MOTS-c (16 amino acids), and six small humanin-like peptides (SHLPs 1-6). They function as signaling molecules that communicate mitochondrial status to the rest of the cell and body, regulating metabolism, inflammation, apoptosis, and stress responses.

What does MOTS-c do?

MOTS-c activates AMPK (the cellular energy sensor), improves insulin sensitivity, and promotes metabolic homeostasis. In mouse studies, MOTS-c prevented obesity on a high-fat diet (Lee et al., Cell Metabolism, 2015) and improved physical capacity in aged mice (Reynolds et al., Nature Communications, 2021). Exercise increases circulating MOTS-c in humans, making it one of the first identified endogenous exercise-mimetic peptides.

Is humanin anti-aging?

Humanin has anti-aging properties in preclinical research. It protects cells from apoptosis, reduces inflammation, and improves cardiac function in aged mice. Centenarians have higher circulating humanin levels than age-matched controls, and long-lived GH receptor knockout mice have elevated humanin (Yen et al., 2020). No human clinical trial has tested humanin as an anti-aging intervention.

Are mitochondrial peptides available as supplements?

No MDP has been approved by the FDA for any indication. MOTS-c has entered early clinical trials for metabolic disease, but results have not been published. Some peptide vendors sell research-grade MOTS-c or humanin analogs, but these products are unregulated, lack clinical dosing data, and have not been tested for long-term safety in humans.

Do mitochondrial-derived peptides decline with age?

Yes. Studies show that circulating humanin levels decline approximately 40% per decade, and MOTS-c levels decrease with age and in metabolic diseases like type 2 diabetes and obesity. This decline parallels the broader deterioration of mitochondrial function that characterizes aging, including reduced respiratory chain efficiency and increased oxidative damage to mitochondrial DNA.

What is the difference between humanin and MOTS-c?

Humanin is a 24-amino-acid peptide encoded in the 16S rRNA gene that primarily protects cells from apoptosis and has been most studied in Alzheimer's disease and cardiac aging models. MOTS-c is a 16-amino-acid peptide encoded in the 12S rRNA gene that primarily activates AMPK and improves metabolic function. Humanin acts mainly as a cytoprotective signal; MOTS-c acts mainly as a metabolic regulator and exercise mimetic.